- Home
- TTRX vs IACQ Comparison
TTRX vs IACQ Comparison
Compare TTRX & IACQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TTRX | IACQ |
|---|---|---|
| Founded | 2015 | 2026 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 298.8M | 322.4M |
| IPO Year | 2025 | 2026 |
Fundamental Metrics
Financial Performance| Metric | TTRX | IACQ |
|---|---|---|
| Price | $10.09 | $9.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | ★ 83.7K | 63.4K |
| Earning Date | 11-25-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $900.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.57 | $9.89 |
| 52 Week High | $16.45 | $10.10 |
Technical Indicators
Market Signals| Indicator | TTRX | IACQ |
|---|---|---|
| Relative Strength Index (RSI) | 42.31 | 49.74 |
| Support Level | $10.05 | $9.89 |
| Resistance Level | $10.72 | $10.00 |
| Average True Range (ATR) | 0.78 | 0.01 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 29.98 | 66.67 |
Price Performance
Historical ComparisonAbout TTRX Turn Therapeutics Inc.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
About IACQ Irenic Acquisition Corp. Class A Ordinary Shares
Irenic Acquisition Corp is a blank check company with no operations.